Abstract
Herpesvirus-based gene therapy vectors offer an attractive alternative to retroviral vectors because of their episomal nature and ability to accommodate large transgenes. Saimiriine herpesvirus 2 (HVS) is a prototypical gamma-2 herpesvirus that can latently infect numerous different cell types. A cosmid-generated HVS vector in which transforming genes have been deleted and the marker gene encoding enhanced green fluorescent protein (HVS-GFP) has been incorporated was evaluated for its potential to transduce CD34+ haemopoietic progenitors selected from cord blood. Expression of GFP could subsequently be readily detected in cells of the erythroid lineage in both CFU-GEMM assays and liquid differentiation cultures. These results confirm the potential of HVS as a candidate vector for gene therapy applications using primitive haemopoietic cells and suggest that it may be applicable to disorders affecting cells of the erythroid lineage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Ward PL, Roizman B . Herpes-simplex virus genes: the blue print of a successful human pathogen. Trends Genet 1984; 10: 267–274.
Glorioso JC, DeLuca NA, Fink DJ . Development and application of herpes-simplex virus vectors for human gene therapy. Ann Rev Microbiol 1995; 49: 675–710.
Fleckenstein B, Desrosiers RC . Herpesvirus saimiri and herpesvirus ateles. In: Roizman B (ed). The Herpes Viruses, Vol. 1. Plenum Publishing Corporation: New York, 1982, pp 253–332.
Simmer B et al. Persistance of selectable herpesvirus saimiri in human haematopoietic and epithelial cell lines. J Gen Virol 1991; 72: 1953–1958.
Stevenson AJ et al. Assessment of herpesvirus saimiri as a potential human gene therapy vector. J Med Virol 1999; 57: 269–277.
Stevenson AJ et al. Herpesvirus saimiri-based gene delivery vectors maintain heterologous expression throughout mouse embryonic stem cell differentiation in vitro. Gene Therapy 2000; 7: 464–471.
Smith PG, Coletta PL, Markham AF, Whitehouse A . In vivo episomal maintenance of a herpesvirus saimiri-based gene delivery vector. Gene Therapy 2001; 8: 1762–1769.
Duboise SM et al. STP and Tip are essential for herpesvirus saimiri oncogenicity. J Virol 1998; 72: 1308–1313.
Frolova-Jones EA et al. Stable marker gene transfer into human bone marrow stromal cells and their progenitors using novel herpesvirus saimiri-based vectors. J Hematother Stem Cell Res 2000; 9: 573–581.
Hogan CJ et al. Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. Blood 1997; 90: 85–96.
Berenson RJ et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717–1722.
Bensinger WI et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88: 4132–4138.
Summers YJ et al. Cord blood G(0) CD34+ cells have a thousand-fold higher capacity for generating progenitors in vitro than G(1) CD34+. Stem Cell 2001; 19: 505–513.
Neildez-Nguyen TM et al. Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivo. Nat Biotechnol 2002; 20: 467–472.
Shaw PH, Olszewski M, Kletzel M . Expansion of megakaryocyte precursors and stem cells from umbilical cord blood CD34+ cells in collagen and liquid culture media. J Hematother Stem Cell Res 2001; 10: 391–403.
de Wynter EA et al. CCR1 chemokine receptor expression isolates erythroid from granulocyte–macrophage progenitors. J Leukocyte Biol 2001; 70: 455–460.
Stevenson AJ et al. A herpesvirus saimiri-based gene therapy vector with potential for use in cancer immunotherapy. Cancer Gene Therapy 2000; 7: 1077–1085.
Schafer A et al. The latency-associated nuclear antigen homolog of herpesvirus saimiri inhibits lytic virus replication. J Virol 2003; 77: 5911–5925.
Verma SC, Robertson ES . ORF73 of herpesvirus saimiri strain C488 tethers the viral genome to metaphase chromosomes and binds to cis-acting DNA sequences in the terminal repeats. J Virol 2003; 77: 12494–12506.
Cotter MA, Robertson ES . The latency-associated nuclear antigen tethers the Kaposi's sarcoma associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. Virology 1999; 264: 254–264.
Ensser A, Thurau M, Wittmann S, Fickenscher H . The genome of herpesvirus saimiri C488 which is capable of transforming human T cells. Virology 2003; 314: 471–487.
Check E . A tragic setback. Nature 2002; 420: 116–118.
Acknowledgements
We thank Liz Straszynski for assistance with flow cytometry and Ewan Morrison for help with microscopy. This work was supported in part by NTRAC, CRUK and Yorkshire Cancer Research. GD is an MRC Research Training Fellow. We thank Dr Adrian Whitehouse for provision of plasmids for probe preparation and Rehka Parma for virus preparation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Doody, G., Leek, J., Bali, A. et al. Marker gene transfer into human haemopoietic cells using a herpesvirus saimiri-based vector. Gene Ther 12, 373–379 (2005). https://doi.org/10.1038/sj.gt.3302422
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302422